Research & Literature

Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma.

Nguyen T, Phillips D, Jain D, et al.

Archives of pathology & laboratory medicine 2015; (139(8)):1028-34 doi:10.5858/arpa.2014-0479-OA.

Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation.

Liu B, Teng F, Fu H, et al.

BMC gastroenterology 2015; (15()):138 doi:10.1186/s12876-015-0364-5.

Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.

Chan AW, Kumada T, Toyoda H, et al.

Journal of gastroenterology and hepatology 2016; (31(7)):1300-6 doi:10.1111/jgh.13291.

Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma.

Nguyen TB, Roncalli M, Di Tommaso L, Kakar S

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016; (29(3)):283-92 doi:10.1038/modpathol.2015.162.

The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study.

Sapisochin G, Goldaracena N, Laurence JM, et al.

Hepatology (Baltimore, Md.) 2016; (64(6)):2077-2088 doi:10.1002/hep.28643.

Hepatocellular carcinoma: From diagnosis to treatment.

Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al.

Surgical oncology 2016; (25(2)):74-85.

Progress in systemic therapy of advanced hepatocellular carcinoma.

Gong XL, Qin SK

World journal of gastroenterology 2016; (22(29)):6582-94 doi:10.3748/wjg.v22.i29.6582.

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

Pecorelli A, Lenzi B, Gramenzi A, et al.

Liver international : official journal of the International Association for the Study of the Liver 2017; (37(3)):423-433 doi:10.1111/liv.13242.

Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.

Choi WT, Ramachandran R, Kakar S

Human pathology 2017; (63()):1-13 doi:10.1016/j.humpath.2016.12.025.

Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US.

Singal AG, Mittal S, Yerokun OA, et al.

The American journal of medicine 2017; (130(9)):1099-1106.e1 doi:10.1016/j.amjmed.2017.01.021.

The importance of a multidisciplinary approach to hepatocellular carcinoma.

Siddique O, Yoo ER, Perumpail RB, et al.

Journal of multidisciplinary healthcare 2017; (10()):95-100 doi:10.2147/JMDH.S128629.

LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.

Santillan C, Fowler K, Kono Y, Chernyak V

Abdominal radiology (New York) 2018; (43(1)):75-81 doi:10.1007/s00261-017-1291-4.

Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function.

Liu JB, Baker TB, Suss NR, et al.

Surgery 2017; (162(5)):1032-1039 doi:10.1016/j.surg.2017.07.017.

Multidisciplinary Management of Hepatocellular Carcinoma Improves Access to Therapy and Patient Survival.

Agarwal PD, Phillips P, Hillman L, et al.

Journal of clinical gastroenterology 2017; (51(9)):845-849 doi:10.1097/MCG.0000000000000825.

Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.

Huang XW, Huang Y, Chen LD, et al.

Journal of medical ultrasonics (2001) 2018; (45(2)):231-241 doi:10.1007/s10396-017-0834-1.

Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function.

Benjamin AJ, Baker TB, Talamonti MS, et al.

Surgery 2018; (163(3)):582-586 doi:10.1016/j.surg.2017.12.005.

Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Burt AD, Alves V, Bedossa P, et al.

Histopathology 2018; (73(3)):369-385 doi:10.1111/his.13520.

The experience of patients participating in a small randomised control trial that explored two different interventions to reduce anxiety prior to an MRI scan.

Tugwell-Allsup J, Pritchard AW

Radiography (London, England : 1995) 2018; (24(2)):130-136 doi:10.1016/j.radi.2017.11.001.

Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and child-pugh (CP) score for predicting of survival in advanced hcc patients receiving radiotherapy (RT).

Ho CHM, Chiang CL, Lee FAS, et al.

Oncotarget 2018; (9(48)):28818-28829 doi:10.18632/oncotarget.25522.

Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.

Stine JG, Wentworth BJ, Zimmet A, et al.

Alimentary pharmacology & therapeutics 2018; (48(7)):696-703 doi:10.1111/apt.14937.

Epidemiology and Management of Hepatocellular Carcinoma.

Kulik L, El-Serag HB

Gastroenterology 2019; (156(2)):477-491.e1 doi:10.1053/j.gastro.2018.08.065.

Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China.

Xu XF, Xing H, Han J, et al.

JAMA surgery 2019; (154(3)):209-217 doi:10.1001/jamasurg.2018.4334.

A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria.

Wang YY, Zhong JH, Xu HF, et al.

Alimentary pharmacology & therapeutics 2019; (49(2)):202-210 doi:10.1111/apt.15074.

Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update.

Kim TH, Kim SY, Tang A, Lee JM

Clinical and molecular hepatology 2019; (25(3)):245-263 doi:10.3350/cmh.2018.0090.

A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.

Wang Y, Yang L, Chen T, et al.

Molecular cancer 2019; (18(1)):28 doi:10.1186/s12943-019-0957-7.

Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis.

Chen ZH, Zhang XP, Wang H, et al.

HPB : the official journal of the International Hepato Pancreato Biliary Association 2019; (21(8)):935-944 doi:10.1016/j.hpb.2019.02.003.

A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma.

Hu KS, Tang B, Yuan J, et al.

Journal of gastroenterology and hepatology 2019; (34(11)):1984-1991 doi:10.1111/jgh.14673.

Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia.

Jasirwan COM, Hasan I, Sulaiman AS, et al.

Current problems in cancer 2020; (44(1)):100480 doi:10.1016/j.currproblcancer.2019.05.003.

Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.

Ioannou GN, Green P, Kerr KF, Berry K

Journal of hepatology 2019; (71(3)):523-533 doi:10.1016/j.jhep.2019.05.008.

Circulating exosomal miR-92b: Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence.

Nakano T, Chen IH, Wang CC, et al.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019; (19(12)):3250-3262 doi:10.1111/ajt.15490.

The Worst from Both Worlds: cHCC-ICC.

Seehawer M, D'Artista L, Zender L

Cancer cell 2019; (35(6)):823-824 doi:10.1016/j.ccell.2019.05.008.

Molecular and histological correlations in liver cancer.

Calderaro J, Ziol M, Paradis V, Zucman-Rossi J

Journal of hepatology 2019; (71(3)):616-630 doi:10.1016/j.jhep.2019.06.001.

Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.

Zech CJ, Ba-Ssalamah A, Berg T, et al.

European radiology 2020; (30(1)):370-382 doi:10.1007/s00330-019-06369-4.

Diagnostic accuracy of quantitative diffusion parameters in the pathological grading of hepatocellular carcinoma: A meta-analysis.

Yang D, She H, Wang X, et al.

Journal of magnetic resonance imaging : JMRI 2020; (51(5)):1581-1593 doi:10.1002/jmri.26963.

Role of liver biopsy in hepatocellular carcinoma.

Di Tommaso L, Spadaccini M, Donadon M, et al.

World journal of gastroenterology 2019; (25(40)):6041-6052 doi:10.3748/wjg.v25.i40.6041.

Switching to systemic therapy after locoregional treatment failure: Definition and best timing.

Ogasawara S, Ooka Y, Koroki K, et al.

Clinical and molecular hepatology 2020; (26(2)):155-162 doi:10.3350/cmh.2019.0021n.

Albumin-Bilirubin Score vs Model for End-Stage Liver Disease in Predicting Post-Hepatectomy Outcomes.

Fagenson AM, Gleeson EM, Pitt HA, Lau KN

Journal of the American College of Surgeons 2020; (230(4)):637-645 doi:10.1016/j.jamcollsurg.2019.12.007.

Microwave ablation after downstaging of hepatocellular carcinoma: outcome was similar to tumor within Milan criteria.

Shi F, Lian S, Mai Q, et al.

European radiology 2020; (30(5)):2454-2462 doi:10.1007/s00330-019-06604-y.

The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.

Zhang J, Chen G, Zhang P, et al.

PloS one 2020; (15(2)):e0228857 doi:10.1371/journal.pone.0228857.

Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis.

Wei T, Zhang XF, Bagante F, et al.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2021; (25(1)):125-133 doi:10.1007/s11605-020-04553-2.

Hepatocellular Carcinoma-How to Determine Therapeutic Options.

Mehta N

Hepatology communications 2020; (4(3)):342-354 doi:10.1002/hep4.1481.

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Finn RS, Qin S, Ikeda M, et al.

The New England journal of medicine 2020; (382(20)):1894-1905 doi:10.1056/NEJMoa1915745.

Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018.

Kang D, Shim S, Cho J, Lim HK

Korean journal of radiology 2020; (21(6)):633-646 doi:10.3348/kjr.2019.0808.

Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC.

Zhao S, Zhang T, Li H, et al.

Annals of translational medicine 2020; (8(8)):538 doi:10.21037/atm.2020.02.124.

Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases.

Feng D, Wang M, Hu J, et al.

Annals of translational medicine 2020; (8(8)):553 doi:10.21037/atm.2020.02.116.

Recurrence beyond the Milan criteria after curative-intent resection of hepatocellular carcinoma: A novel tumor-burden based prediction model.

Tsilimigras DI, Mehta R, Guglielmi A, et al.

Journal of surgical oncology 2020; (122(5)):955-963 doi:10.1002/jso.26091.

CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.

Lee S, Kim YY, Shin J, et al.

Journal of the American College of Radiology : JACR 2020; (17(10)):1199-1206 doi:10.1016/j.jacr.2020.06.005.

Benign Hepatic Nodules Mimicking Hepatocellular Carcinoma in the Setting of Fontan-associated Liver Disease: A Case Report.

Çolaklar A, Lehnert SJ, Tirkes T

Euroasian journal of hepato-gastroenterology 2020; (10(1)):42-44 doi:10.5005/jp-journals-10018-1315.

Clinical outcomes of patients with a high alpha-fetoprotein level but without evident recurrence on CT or MRI in surveillance after curative-intent treatment for hepatocellular carcinoma.

Lee J, Joo I, Lee DH, et al.

Abdominal radiology (New York) 2021; (46(2)):597-606 doi:10.1007/s00261-020-02707-z.

Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B.

Lee HW, Yip TC, Tse YK, et al.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2021; (19(9)):1950-1958.e7 doi:10.1016/j.cgh.2020.08.064.

Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma.

Chen LJ, Chang YJ, Chang YJ

The oncologist 2021; (26(3)):e445-e453 doi:10.1002/onco.13535.

New advances in the diagnosis and management of hepatocellular carcinoma.

Yang JD, Heimbach JK

BMJ (Clinical research ed.) 2020; (371()):m3544 doi:10.1136/bmj.m3544.

Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.

Badran H, Elsabaawy MM, Ragab A, et al.

Asian Pacific journal of cancer prevention : APJCP 2020; (21(11)):3285-3290 doi:10.31557/APJCP.2020.21.11.3285.

Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

Marasco G, Colecchia A, Bacchi Reggiani ML, et al.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2021; (53(8)):1011-1019 doi:10.1016/j.dld.2020.12.001.

Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature.

Campigotto M, Giuffrè M, Colombo A, et al.

World journal of hepatology 2020; (12(12)):1239-1257 doi:10.4254/wjh.v12.i12.1239.

Multiple hepatocellular carcinoma: Long-term outcomes following resection beyond actual guidelines. An Italian multicentric retrospective study.

Bartolini I, Nelli T, Russolillo N, et al.

American journal of surgery 2021; (222(3)):599-605 doi:10.1016/j.amjsurg.2021.01.023.

Deep Learning With 3D Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma.

Zhang Y, Lv X, Qiu J, et al.

Journal of magnetic resonance imaging : JMRI 2021; (54(1)):134-143 doi:10.1002/jmri.27538.

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Benson AB, D'Angelica MI, Abbott DE, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(5)):541-565.

Establishment and Evaluation of a Predictive Model for Early Postoperative Recurrence of Hepatocellular Carcinoma in Patients with Microvascular Invasion.

Zhang K, Tao C, Wu F, et al.

International journal of general medicine 2021; (14()):2259-2274 doi:10.2147/IJGM.S303896.

Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course.

van Rosmalen BV, Furumaya A, Klompenhouwer AJ, et al.

Liver international : official journal of the International Association for the Study of the Liver 2021; (41(10)):2474-2484 doi:10.1111/liv.14989.

Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma.

Younossi ZM, Henry L

JHEP reports : innovation in hepatology 2021; (3(4)):100305 doi:10.1016/j.jhepr.2021.100305.

Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.

Salem R, Li D, Sommer N, et al.

Cancer medicine 2021; (10(16)):5437-5447 doi:10.1002/cam4.4090.

Histological Heterogeneity of Primary Liver Cancers: Clinical Relevance, Diagnostic Pitfalls and the Pathologist's Role.

Komuta M

Cancers 2021; (13(12)) doi:10.3390/cancers13122871.

Recent advances in the surgical management of hepatocellular carcinoma.

Glantzounis GK, Karampa A, Peristeri DV, et al.

Annals of gastroenterology 2021; (34(4)):453-465 doi:10.20524/aog.2021.0632.

Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma.

Gok Yavuz B, Hasanov E, Lee SS, et al.

Journal of hepatocellular carcinoma 2021; (8()):1195-1207 doi:10.2147/JHC.S322289.

CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.

van der Pol CB, McInnes MDF, Salameh JP, et al.

Radiology 2022; (302(2)):326-335 doi:10.1148/radiol.2021211244.

Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.

Piratvisuth T, Tanwandee T, Thongsawat S, et al.

Hepatology communications 2022; (6(4)):679-691 doi:10.1002/hep4.1847.

What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?

Ghadimi M, Birnbaum J, Kamel IR, et al.

European radiology 2022; (32(5)):3327-3333 doi:10.1007/s00330-021-08389-5.

Consensus on the secondary prevention of primary liver cancer.

Nan Y, Xu X, Gao Y, et al.

Hepatology international 2021; (15(6)):1289-1300 doi:10.1007/s12072-021-10259-7.

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

Cheng AL, Qin S, Ikeda M, et al.

Journal of hepatology 2022; (76(4)):862-873 doi:10.1016/j.jhep.2021.11.030.

MRI-diagnosis of category LR-M observations in the Liver Imaging Reporting and Data System v2018: a systematic review and meta-analysis.

Shin J, Lee S, Hwang JA, et al.

European radiology 2022; (32(5)):3319-3326 doi:10.1007/s00330-021-08382-y.

Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).

Parameswaran M, Hasan HA, Sadeque J, et al.

Cureus 2021; (13(12)):e20776 doi:10.7759/cureus.20776.

A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review.

Awosika J, Sohal D

Journal of gastrointestinal oncology 2022; (13(1)):426-437 doi:10.21037/jgo-21-274.

Hepatocellular Carcinoma in Evolution: Correlation with CEUS LI-RADS.

Nguyen SA, Merrill CD, Burrowes DP, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2022; (42(4)):1028-1042 doi:10.1148/rg.210149.

Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.

Zhang X, Huang WJ, Zhang ML, et al.

BMC gastroenterology 2022; (22(1)):288 doi:10.1186/s12876-022-02348-0.

New concepts in the treatment of hepatocellular carcinoma.

Sidali S, Trépo E, Sutter O, Nault JC

United European gastroenterology journal 2022; (10(7)):765-774 doi:10.1002/ueg2.12286.

Liver Imaging Reporting and Data System criteria for the diagnosis of hepatocellular carcinoma in clinical practice: A pictorial minireview.

Liava C, Sinakos E, Papadopoulou E, et al.

World journal of gastroenterology 2022; (28(32)):4540-4556 doi:10.3748/wjg.v28.i32.4540.

Prevalence of benign focal liver lesions and non-hepatocellular carcinoma malignant lesions in liver cirrhosis.

Möller K, Safai Zadeh E, Görg C, et al.

Zeitschrift fur Gastroenterologie 2023; (61(5)):526-535 doi:10.1055/a-1890-5818.

Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.

Tian BW, Yan LJ, Ding ZN, et al.

International immunopharmacology 2023; (114()):109519 doi:10.1016/j.intimp.2022.109519.

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.

Song X, Kelley RK, Khan AA, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(4)):754-763 doi:10.1158/1078-0432.CCR-22-1983.

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world.

Feng JK, Liu ZH, Fu ZG, et al.

Frontiers in oncology 2022; (12()):954203 doi:10.3389/fonc.2022.954203.

Systemic analysis identifying PVT1/DUSP13 axis for microvascular invasion in hepatocellular carcinoma.

Su R, Zhang H, Zhang L, et al.

Cancer medicine 2023; (12(7)):8937-8955 doi:10.1002/cam4.5546.

Effect of multi-disciplinary team care program on quality of life, anxiety, and depression in hepatocellular carcinoma patients after surgery: A randomized, controlled study.

Yang L, Yan C, Wang J

Frontiers in surgery 2022; (9()):1045003 doi:10.3389/fsurg.2022.1045003.

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective.

Su TH, Wu CH, Liu TH, et al.

Clinical and molecular hepatology 2023; (29(2)):230-241 doi:10.3350/cmh.2022.0421.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Predictors of early and late hepatocellular carcinoma recurrence.

Nevola R, Ruocco R, Criscuolo L, et al.

World journal of gastroenterology 2023; (29(8)):1243-1260 doi:10.3748/wjg.v29.i8.1243.

Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

Dunsmore VJ, Neupert SD

Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy.

Hatanaka T, Yata Y, Naganuma A, Kakizaki S

Cancers 2023; (15(6)) doi:10.3390/cancers15061798.

Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study.

Yan WT, Li C, Yao LQ, et al.

Hepatobiliary surgery and nutrition 2023; (12(2)):155-168 doi:10.21037/hbsn-21-288.

The current landscape of therapies for hepatocellular carcinoma.

Coffman-D'Annibale K, Xie C, Hrones DM, et al.

Carcinogenesis 2023; (44(7)):537-548 doi:10.1093/carcin/bgad052.

Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion.

Taouli B, Ba-Ssalamah A, Chapiro J, et al.

European radiology 2023; (33(12)):9167-9181 doi:10.1007/s00330-023-09919-z.

Application and progress of the detection technologies in hepatocellular carcinoma.

Yan Q, Sun YS, An R, et al.

Genes & diseases 2023; (10(5)):1857-1869 doi:10.1016/j.gendis.2022.04.003.

Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma.

Ahmed Z, Lee SS, Victor DW, Kodali S

Journal of hepatocellular carcinoma 2023; (10()):1911-1922 doi:10.2147/JHC.S395080.

Differentiation of Hepatocellular Carcinoma from Intrahepatic Cholangiocarcinoma through MRI Radiomics.

Liu N, Wu Y, Tao Y, et al.

Cancers 2023; (15(22)) doi:10.3390/cancers15225373.

Prognostic potential of preoperative circulating tumor cells to predict the early progression recurrence in hepatocellular carcinoma patients after hepatectomy.

Lu Z, Ni H, Yang X, et al.

BMC cancer 2023; (23(1)):1150 doi:10.1186/s12885-023-11629-0.

Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab.

Ledenko M, Mercado L, Patel T

American journal of clinical oncology 2024; (47(3)):105-109 doi:10.1097/COC.0000000000001067.

Effect of multidisciplinary team care on patient survival in chronic hepatitis B or C hepatocellular carcinoma.

Tseng YC, Kung PT, Peng CY, et al.

Frontiers in oncology 2023; (13()):1251571 doi:10.3389/fonc.2023.1251571.

Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease.

Thomas JA, Kendall BJ, El-Serag HB, et al.

The lancet. Gastroenterology & hepatology 2024; (9(2)):159-169 doi:10.1016/S2468-1253(23)00275-3.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Application of Machine Learning Techniques to Assess Alpha-Fetoprotein at Diagnosis of Hepatocellular Carcinoma.

Gil-Rojas S, Suárez M, Martínez-Blanco P, et al.

International journal of molecular sciences 2024; (25(4)) doi:10.3390/ijms25041996.

Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?

Himmelsbach V, Koch C, Trojan J, Finkelmeier F

Journal of hepatocellular carcinoma 2024; (11()):363-372 doi:10.2147/JHC.S443218.

Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.

Rimini M, Stefanini B, Tada T, et al.

Liver international : official journal of the International Association for the Study of the Liver 2024; (44(5)):1108-1125 doi:10.1111/liv.15885.

Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.

Kim DY

Journal of liver cancer 2024; (24(1)):62-70 doi:10.17998/jlc.2024.03.13.

Diagnosis of the Initial Stage of Hepatocellular Carcinoma: A Review.

Sharma KK, Mohsin M, Mittal P, et al.

Current pharmaceutical design 2024; (30(22)):1708-1724 doi:10.2174/0113816128298875240321073907.

Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?

Werner W, Kuzminskaya M, Lurje I, et al.

Seminars in liver disease 2024; (44(2)):159-179 doi:10.1055/a-2334-8311.

Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.

Ai H, Gong T, Ma Y, et al.

Frontiers in immunology 2024; (15()):1358602 doi:10.3389/fimmu.2024.1358602.

Gd-EOB-DTPA enhanced MRI nomogram model to differentiate hepatocellular carcinoma and focal nodular hyperplasia both showing iso- or hyperintensity in the hepatobiliary phase.

Mao HY, Shen BQ, Zhang JY, et al.

BMC medical imaging 2024; (24(1)):211 doi:10.1186/s12880-024-01382-6.

Evolving Global Etiology of Hepatocellular Carcinoma (HCC): Insights and Trends for 2024.

Koshy A

Journal of clinical and experimental hepatology 2025; (15(1)):102406 doi:10.1016/j.jceh.2024.102406.

Surgical Treatment of Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease: A Report of Three Cases.

Rinka K, Kioka K, Amano Y, et al.

Internal medicine (Tokyo, Japan) 2025; (64(12)):1834-1842 doi:10.2169/internalmedicine.4631-24.

The Changing Demographics and Epidemiology of Hepatocellular Carcinoma.

Gujarathi R, Klein JA, Liao CY, Pillai A

Clinics in liver disease 2025; (29(1)):1-15 doi:10.1016/j.cld.2024.08.001.

Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study.

Kim KP, Kim KM, Ryoo BY, et al.

Liver cancer 2024; (13(6)):610-628 doi:10.1159/000539724.

Chronological changes in etiology, pathological and imaging findings in primary liver cancer from 2001 to 2020.

Tsuzaki J, Ueno A, Masugi Y, et al.

Japanese journal of clinical oncology 2025; (55(4)):362-371 doi:10.1093/jjco/hyae187.

Systemic therapy for hepatocellular carcinoma, from the early to the advanced stage: a Japanese perspective.

Ikeda M, Morizane C, Ueno M, et al.

Japanese journal of clinical oncology 2025; (55(5)):465-476 doi:10.1093/jjco/hyaf017.

Development and validation of a combined radiomic and clinical model based on contrast-enhanced ultrasound for preoperative prediction of CK19-positive hepatocellular carcinoma.

Liang L, Pang JS, Gao RZ, et al.

Abdominal radiology (New York) 2025; (50(8)):3516-3529 doi:10.1007/s00261-025-04799-x.

A Rare Case of Hepatocellular Carcinoma Presenting as Cervical Lymph Node Metastases and Review of the Literature.

Tkachuk B, Stukalin I, Wang Y, Congly SE

ACG case reports journal 2025; (12(2)):e01620 doi:10.14309/crj.0000000000001620.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Impacts Long-Term Outcomes After Curative-Intent Surgery for Hepatocellular Carcinoma.

Uluk D, Pein J, Herda S, et al.

Alimentary pharmacology & therapeutics 2025; (61(8)):1318-1332 doi:10.1111/apt.70002.

Impact of compliance to postoperative regular follow-up on long-term prognosis after curative resection for hepatocellular carcinoma: A multicenter analysis.

Yao LQ, Gong JB, Cai L, et al.

Hepatobiliary & pancreatic diseases international : HBPD INT 2025; (24(3)):261-268 doi:10.1016/j.hbpd.2025.03.003.

Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis.

Piñero F, Anders M, Bermudez C, et al.

Liver international : official journal of the International Association for the Study of the Liver 2025; (45(5)):e70092 doi:10.1111/liv.70092.

Model of End-Stage Liver Disease-alpha-fetoprotein-tumor burden (MELD-AFP-TBS) score to stratify prognosis after liver resection for hepatocellular carcinoma.

Kawashima J, Akabane M, Khalil M, et al.

Surgery 2025; (183()):109388 doi:10.1016/j.surg.2025.109388.

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.

Yau T, Galle PR, Decaens T, et al.

Lancet (London, England) 2025; (405(10492)):1851-1864 doi:10.1016/S0140-6736(25)00403-9.

Clinically Uncertain Liver Masses: A Guide to Distinguishing Poorly Differentiated Primary Liver Cancer.

Sökeland G, Brönnimann MP, Vassella E, et al.

Biomedicines 2025; (13(5)) doi:10.3390/biomedicines13051063.

Developing Cancer Quality of Care Indicators to Quantify the Impact of a Global Destabilization of the Care System (COLLAT-COVID).

Piazzon N, Haesebaert J, Michel P, et al.

Cancers 2025; (17(10)) doi:10.3390/cancers17101680.

Multidisciplinary teams in clinical lipidology and cardiometabolic care: A National Lipid Association Expert Clinical Review.

Cheeley MK, Kirkpatrick CF, Brown EE, et al.

Journal of clinical lipidology 2025; (19(4)):737-747 doi:10.1016/j.jacl.2025.05.002.

Distinct patterns of late recurrence in long-term hepatocellular carcinoma survivors.

Akabane M, Kawashima J, Woldesenbet S, et al.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2025; (29(9)):102135 doi:10.1016/j.gassur.2025.102135.

Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma.

Cabibbo G, Celsa C, Bhoori S, et al.

Journal of hepatology 2025; (83(6)):1443-1451 doi:10.1016/j.jhep.2025.07.020.

Health-related quality of life in Thai patients with hepatocellular carcinoma and its influencing factors: A cross-sectional study.

Pathomjaruwat T, Matchim Y, Armer JM

Belitung nursing journal 2025; (11(4)):370-383 doi:10.33546/bnj.3853.

Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.

Jaber F, Cholankeril G, El-Serag HB

Journal of the Canadian Association of Gastroenterology 2024; (7(5)):331-345 doi:10.1093/jcag/gwae025.

Advancing predictive oncology: Integrating clinical and radiomic models to optimize transarterial chemoembolization outcomes in hepatocellular carcinoma.

Baddam S

World journal of clinical cases 2025; (13(28)):109397 doi:10.12998/wjcc.v13.i28.109397.

Development and Validation of an Individualized Prediction Model for Postoperative Late Recurrence After Hepatectomy for Hepatocellular Carcinoma (POLAR-HCC): A Multicenter Study.

Xu XF, Wu H, Gu LH, et al.

Annals of surgical oncology 2025; (32(13)):9573-9583 doi:10.1245/s10434-025-18213-9.

Clinical performance of GAAD score, alpha-fetoprotein, and PIVKA-II in diagnosing hepatocellular carcinoma in the Vietnamese cohort.

Pham TTT, Ho DT, Nguyen TB, Phan HT

Discover oncology 2025; (16(1)):1813 doi:10.1007/s12672-025-03651-4.

Impact of the 6-mo Wait Policy on Transplantation, Resection, and Ablation Outcomes for Patients With Hepatocellular Carcinoma: A National Cancer Database Analysis.

Hasjim BJ, Paukner M, Kwong AJ, et al.

Transplantation 2026; (110(1)):e204-e216 doi:10.1097/TP.0000000000005536.

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.

Reig M, Sanduzzi-Zamparelli M, Forner A, et al.

Journal of hepatology 2026; (84(3)):631-654 doi:10.1016/j.jhep.2025.10.020.

The platelet-albumin-bilirubin score in predicting hepatic failure after TACE for non-small hepatocellular carcinoma.

Liang W, Yuan H, Zhou J, et al.

Postgraduate medicine 2025; 1-8 doi:10.1080/00325481.2025.2587342.

Efficacy and safety of immune checkpoint inhibitors combined with anti-angiogenic agents compared to sorafenib or lenvatinib in the treatment of unresectable or advanced hepatocellular carcinoma a pairwise meta-analysis of randomized controlled trials.

Liu Z, Jiang Y, Deng Y, Liu J

International journal of surgery (London, England) 2025; doi:10.1097/JS9.0000000000004156.